IPO Year: 2014
Exchange: NASDAQ
6-K - Altamira Therapeutics Ltd. (0001601936) (Filer)
6-K - Altamira Therapeutics Ltd. (0001601936) (Filer)
6-K - Altamira Therapeutics Ltd. (0001601936) (Filer)
6-K - Altamira Therapeutics Ltd. (0001601936) (Filer)
424B4 - Altamira Therapeutics Ltd. (0001601936) (Filer)
EFFECT - Altamira Therapeutics Ltd. (0001601936) (Filer)
F-1/A - Altamira Therapeutics Ltd. (0001601936) (Filer)
F-1/A - Altamira Therapeutics Ltd. (0001601936) (Filer)
F-1 - Altamira Therapeutics Ltd. (0001601936) (Filer)
EFFECT - Altamira Therapeutics Ltd. (0001601936) (Filer)
Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its First Half 2024 Financial Results and Business Update Call on Tuesday, September 24, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts. Webcast Access: Event: Altamira Therapeutics First Half 2024 Financial Results and Business Update CallDate: Tuesday, September 24, 2024Time: 8:30 am ET We
Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its Full Year 2023 Financial Results and Business Update Call on Friday, April 10, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts. Webcast Access: Event: Altamira Therapeutics Full Year 2023 Financial Results and Business Update CallDate: Wednesday, April 10, 2024Time: 8:30 am EDTWebcast URL
HAMILTON, BERMUDA , Dec. 05, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA--December 5, 2023--Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it will host an Investor and Business Update Call on Monday, December 11, 2023, 8:30 a.m. ET. The presentation will be available via teleconference or webcast with audio and presenter-controlled slides. Webcast Access: Date: Monday, December 11, 2023Time: 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)Webcast URL: https://edge.media-server.com/mmc/p/k7s8zdkg Register for Teleconference:
Covadonga Pañeda, Ph.D., to join leadership team as Chief Development Officer for RNA therapeuticsReceipt of NIH grant to help advance siRNA delivery platform for use in extrahepatic inflammatory disordersHAMILTON, BERMUDA / ACCESSWIRE / January 13, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today provided a business update on its development activities in RNA therapeutics.Growing the Leadership TeamAs part of its ongoing repositioning around RNA therapeutics, the Company is expanding its leadership team with the appointment of Covadonga Pa
HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Trading to continue under ticker symbol "CYTOF"No reverse stock split planned Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that on December 18, 2024 it received notice that the Nasdaq Hearings Panel (the "Panel") had determined to delist the Company's common shares from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of $1.00 per share. The Com
Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that it no longer complied with Rule 5550(a)(2) of Nasdaq's Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company's listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. The letter stated that the Company is not eligible for any cure period
Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Certification to ISO 13485 extended to also include production process Supports Bentrio growth strategy together with strategic contract manufacturer and expanding network of international distributors Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO) today announced that its associate company Altamira Medica Ltd. obtained extended ISO 13485 certification for its quality management system, including henceforth also production activities. With this extension, the quality management system has been certified for the whole design, development, production and distribution cycle for Altamira Medica's Bentrio® nasal
Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ETContinued progress within core activities in RNA delivery, supported by move into new R&D facilities Publications by independent research groups provide fresh evidence of effective mRNA delivery to extrahepatic targets Major territory expansion with two distribution partners for Bentrio® Financial results presented for first time in US dollars rather than Swiss francs Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business
Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its First Half 2024 Financial Results and Business Update Call on Tuesday, September 24, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts. Webcast Access: Event: Altamira Therapeutics First Half 2024 Financial Results and Business Update CallDate: Tuesday, September 24, 2024Time: 8:30 am ET We
Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked warrants Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the closing of its previously announced public offering of an aggregate of 5,555,556 common shares (or pre-funded warrants in lieu thereof) accompanied by Series A-1 common warrants to purchase up to 5,555,556 common shares and Series A-2 common warrants to purchase up to 5,555,556 common sh
Hamilton, Bermuda, Sept. 17, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked warrants Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the pricing of a public offering of an aggregate of 5,555,556 common shares (or pre-funded warrants in lieu thereof) accompanied by Series A-1 common warrants to purchase up to 5,555,556 common shares and Series A-2 common warrants to purchase up to 5,555,556 common shares, at a combined
Hamilton, Bermuda, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing authorization for Mainland China Extension of Exclusive License and Distribution Agreement to include seven additional countries across East and South East Asia with cumulated population > 630 million Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO) today announced that its associate company Altamira Medica Ltd. has agreed with its partner Nuance Pharma, Shanghai, China ("Nuance") to extend the territory covered by their exclusive license and distribution agreement
Hamilton, Bermuda, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, being held virtually and in person on September 9-11, 2024, at Lotte New York Palace Hotel in New York City. Event: H.C. Wainwright Presentation On-Demand Date: September 09, 2024 Time: 7:00am ET Webcast: Link Registration: Link Please note that Company presentation date and time are subject to change.
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on Altamira Therapeutics Ltd. (NASDAQ:CYTO). The update note includes detailed information on Altamira Therapeutic's management commentary, recent developments, outlook, and risks. The update note is available here. Highlights from the note include: Announces Significant Enhancement of Immune Checkpoint Inhibitor Therapy Using Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models: Altamira Therapeutics has revealed promising outcomes from a study combining Zbtb46 mRNA, delivered via their
SC 13G - Altamira Therapeutics Ltd. (0001601936) (Subject)
SC 13D/A - Altamira Therapeutics Ltd. (0001601936) (Subject)
SC 13D/A - Altamira Therapeutics Ltd. (0001601936) (Subject)
SC 13D/A - Altamira Therapeutics Ltd. (0001601936) (Subject)
SC 13D/A - Altamira Therapeutics Ltd. (0001601936) (Subject)
SC 13D/A - Altamira Therapeutics Ltd. (0001601936) (Subject)
Hamilton, Bermuda, April 10, 2024 (GLOBE NEWSWIRE) -- Management to host conference call today, April 10, at 8.30 a.m. EDTRNA delivery business progressing with new collaborations, potential new applicationsPartnering of legacy assets underway as Company transitions to focused RNA delivery technology providerAchieved 85% reduction in net loss to CHF 3.9 million and eliminated financial debtFinished year with shareholders' equity of CHF 6.5 million, improved by CHF 14.8 million HAMILTON, BERMUDA -- April 10, 2024 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond th
Management will host an investor conference call today, May 16th, at 8 a.m. EasternCompany is advancing OligoPhore™ / SemaPhore™ platform for extrahepatic RNA delivery and efficient endosomal release; expects first research collaborations with biopharmaceutical companies in 2023Filed IND submission with FDA for AM-125 in acute vestibular syndrome‘Showcase' RNA development programs AM-401 and AM-411 progressing in KRAS-driven cancers and rheumatoid arthritis, targeting INDs in 2024Divestiture or partnering of legacy assets remains a key strategic focusTop-line data from full NASAR trial with Bentrio in seasonal allergic rhinitis expected in the second quarterHAMILTON, BERMUDA / ACCESSWIRE / M
Management will host an investor conference call today, Tuesday, at 8 a.m. Eastern.Company pivots towards RNA therapeutics and its OligoPhore™ / SemaPhore™ platform for extrahepatic RNA deliverEstablished new business unit, OTC Consumer Health, to support global commercialization of Bentrio nasal spray and successfully established distribution partners covering more than 20 countries so far.Reported completion of enrollment into Bentrio™ house dust mite clinical trial with expected top-line results planned for 2Q-22, and initiation of "COVAMID" clinical trial in acute COVID-19.Completed patient enrollment in Part B of Phase 2 ‘TRAVERS' clinical trial evaluating AM-125 in acute vertigo; expec
HAMILTON, BERMUDA / ACCESSWIRE / April 4, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced it will hold an investor call on Tuesday, April 12, 2022, 8:00 a.m. ET to discuss its full-year 2021 earnings. The presentation will be available via teleconference or webcast with audio and presenter-controlled slides.Date: Wednesday, April 12, 2022 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time)Webcast URL: https://www.webcaster4.com/Webcast/Page/2797/45151Toll-free dial-in number: 877-545-0320International dial-in number: 973-528-0002Participant Access Code: 786152Participants will be greeted b
Building Bentrio™ brand and expanding in European markets510(k) premarket notification for allergy indication submitted to the U.S. Food and Drug Administration ("FDA")Distributors signed up for two key South East Asian countries, highlighting international expansion potentialHAMILTON, BERMUDA / ACCESSWIRE / September 27, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today provided a business update on Bentrio™, its nasal spray for protection against airborne viruses and allergens.Bentrio™ was launched first in Germany under CE mark in late Ju
HAMILTON, BERMUDA / ACCESSWIRE / September 21, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that it will provide a business update on Bentrio™, its nasal spray for protection against airborne viruses and allergens, through a live conference call and webcast on Monday, September 27, 2021, at 8:00 AM Eastern Time.To participate telephonically, please dial (888) 506-0062 (U.S.) or (973) 528-0011 (international), conference code 590321. A live, listen-only webcast of the conference call, which will include accompanying slides, can